Corpus Intelligence IC Memo — LVH - COORDINATED BETHLEHEM 2026-04-26 17:42 UTC
IC Memo — LVH - COORDINATED BETHLEHEM
Investment Committee Memorandum | PA | 20 beds | Grade C | EBITDA uplift $1.7M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

LVH - COORDINATED BETHLEHEM

CCN 390314 | NORTHAMPTON, PA | 20 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

LVH - COORDINATED BETHLEHEM is a 20-bed suburban community hospital in NORTHAMPTON, PA with $23.5M in net patient revenue and a 25.6% operating margin. The hospital serves a payer mix of 30.8% Medicare, 1.5% Medicaid, and 67.7% commercial.

Thesis: Turnaround. Our ML models identify $1.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 25.6% to 33.0% (+736bps).

Net Revenue HCRIS$23.5M
Current EBITDA COMPUTED$6.0M
Operating Margin COMPUTED25.6%
Occupancy HCRIS6.5%
Revenue / Bed COMPUTED$1.2M
Net-to-Gross HCRIS27.6%
Distress Probability ML57.2%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
46
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of 25.6% places it above the state median. Among 46 size-comparable peers (10-40 beds), the median margin is -0.1%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (10-40), prioritizing same-state peers. 46 hospitals in the comp set.

HospitalStateBedsRevenueMargin
LVH - COORDINATED BETHLEHEM (Target)PA20$23.5M25.6%
OSS ORTHOPAEDIC HOSPITALPA30$149.4M-5.0%
WELLSPAN SURGERY AND REHAB HOSPA25$120.2M2.8%
UPMC LITITZPA36$114.5M14.2%
LVH-COORDINATED ALLENTOWNPA20$89.6M2.3%
CHARLES COLE MEMORIAL HOSPITALPA25$88.1M-9.0%
POCONO MEDICAL CENTER DICKSON PA40$85.9M0.1%
WELLSBOROPA25$85.6M2.3%
GEISINGER BLOOMSBURG HOSPITALPA40$75.3M6.5%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $1.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$493K+210bp18mo
Cost to Collect4.5%2.5%$470K+200bp12mo
Denial Rate Reduction12.0%6.5%$465K+198bp12mo
A/R Days Reduction5200.0%3800.0%$286K+122bp9mo
Clean Claim Rate88.0%96.0%$15K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$493K
Cost to Collect
$470K
Denial Rate Reduction
$465K
A/R Days Reduction
$286K
Clean Claim Rate
$15K
Total EBITDA Uplift$1.7M
Current EBITDA$6.0M
+ RCM Uplift+$1.7M
Pro Forma EBITDA$7.7M
Current Margin25.6%
Pro Forma Margin33.0%
WC Released (1x)$901K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$9.2M$56.9M6.16x43.8%
Base (11x exit)10.0x11.0x$9.2M$65.6M7.10x48.0%
Bull Case9.0x11.0x$8.3M$74.3M8.93x54.9%
Bull (12x exit)9.0x12.0x$8.3M$83.6M10.04x58.6%
Bear Case11.0x10.0x$10.2M$45.3M4.45x34.8%
Bear (11x exit)11.0x11.0x$10.2M$53.1M5.22x39.2%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 6.5%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 57.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 46 hospitals with 10-40 beds
  • Same-state prioritization (n=47)
  • Comp margins: P25=-13.3% / P50=-0.1% / P75=7.3%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.